JACC. Case reports · 2025
Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy During Active Chemotherapy.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Caro-Codón Juan, Valbuena-López Silvia, Ghanem Cañete Ismael, Pérez Wert Juan Pablo, Refoyo Elena, Fernández García-Moya Luis, Saldaña-García Jesús, Paños-Babin Maria, Moreno Raúl, López-Fernández Teresa
Аннотация
BACKGROUND: The role of cardiac myosin inhibitors in patients with obstructive hypertrophic cardiomyopathy (oHCM) and active malignancy remains unexplored.
CASE SUMMARY: A 68-year-old woman with colon cancer presented with worsening dyspnea. Echocardiography showed severe asymmetric septal hypertrophy, systolic anterior motion of the mitral valve, and a peak left ventricular outflow tract gradient of 115 mm Hg. Beta-blocker therapy failed to control symptoms. After multidisciplinary cardio-oncology evaluation, mavacamten therapy was initiated. Within 4 weeks, the patient's left ventricular outflow tract gradient decreased to 10 mm Hg, her NYHA functional class improved to I, and her NT-proBNP levels dropped markedly. Chemotherapy continued without interruption. Nine months later, her oncologic disease progressed, and palliative care was adopted.
DISCUSSION: This case highlights mavacamten as a safe and effective therapy for oHCM in a patient actively receiving chemotherapy. It underscores the potential value of cardiac myosin inhibition in complex comorbid scenarios.
TAKE-HOME MESSAGE: Mavacamten can substantially improve quality of life in oHCM, even in patients with active malignancy.
CASE SUMMARY: A 68-year-old woman with colon cancer presented with worsening dyspnea. Echocardiography showed severe asymmetric septal hypertrophy, systolic anterior motion of the mitral valve, and a peak left ventricular outflow tract gradient of 115 mm Hg. Beta-blocker therapy failed to control symptoms. After multidisciplinary cardio-oncology evaluation, mavacamten therapy was initiated. Within 4 weeks, the patient's left ventricular outflow tract gradient decreased to 10 mm Hg, her NYHA functional class improved to I, and her NT-proBNP levels dropped markedly. Chemotherapy continued without interruption. Nine months later, her oncologic disease progressed, and palliative care was adopted.
DISCUSSION: This case highlights mavacamten as a safe and effective therapy for oHCM in a patient actively receiving chemotherapy. It underscores the potential value of cardiac myosin inhibition in complex comorbid scenarios.
TAKE-HOME MESSAGE: Mavacamten can substantially improve quality of life in oHCM, even in patients with active malignancy.